Journal of Clinical Oncology
Articles in this Issue
Real-world outcomes with nivolumab–ipilimumab in metastatic renal cell carcinoma by nephrectomy status: A single-center study.
e16546 Background: Following the results of the CARMENA trial, the role of cytoreductive nephrectomy in the era of targete...
Pharmacokinetic (PK) assessment of revumenib in patients with relapsed/refractory (R/R) acute leukemias harboring a <i>KMT2A</i> rearrangement ( <i>KMT2A</i> r) or <i>NPM1</i> mutation ( <i>NPM1</i> m): Impact of food and concomitant medications.
6528 Background: Revumenib is a first-in-class, oral, potent, and selective inhibitor of the menin-KMT2A interaction that...
A transcriptomic signature to predict immune checkpoint inhibition efficacy in proficient mismatch repair metastatic colorectal cancer: Translational analysis of the AVETRIC and TRIPLETE studies.
3570 Background: ICIs provide limited benefit in proficient mismatch repair (pMMR) metastatic colorectal cancer (mCRC), hi...
Neuropathy following chimeric antigen receptor T-cell therapy: Incidence and associated risk factors.
e23448 Background: Neurotoxicity associated with chimeric antigen receptor T-cell (CAR-T) therapy, particularly immune eff...
Phase I/IIa dose finding study of triplet regimen of relatlimab (RELA) ipilimumab (IPI), and nivolumab (NIVO) in first-line therapy of metastatic melanoma (MM) (TRINITY).
TPS9603 Background: Approved immune checkpoint blockade (ICB) agents for the treatment (tx) advanced, unresectable metasta...
Time to transplant by sociodemographic group following MELD 3.0 implementation in hepatocellular carcinoma.
e23208 Background: The MELD 3.0 policy was implemented in July 2023 to improve mortality prediction and address allocation...
Outcomes of radical radiotherapy in de novo low-burden metastatic hormone-sensitive prostate cancer vs prostate radiotherapy alone.
5097 Background: The current standard of care (SoC) for metastatic hormone-sensitive prostate cancer (mHSPC) is androgen d...
A phase II, exploratory trial of cadonilimab (AK104) plus gemcitabine-cisplatin (GC) as a conversion therapy for patients (pts) with unresectable or systemic treatment–failed biliary tract cancer (BTC).
e16177 Background: PD-(L)1 inhibitor combined with GC is an established first-line treatment for unresectable BTC. However...
Addition of 18F-DCFPyL PSMA PET to MRI to avoid unnecessary biopsy in men on active surveillance: Final results from a phase II diagnostic trial (PROMPT).
5125 Background: Multiparametric MRI (mpMRI) is used in active surveillance (AS) for prostate cancer (PC) but has limited...
The impact of body composition on cardiac function in women with early breast cancer taking cardiotoxic chemotherapy.
12021 Background: Anthracyclines and HER2-directed therapies have improved survival in early breast cancer (EBC), but card...
Pseudoprogression after neoadjuvant immunotherapy for resectable NSCLC: Incidence, PET/CT patterns, and differentiation.
8032 Background: Neoadjuvant immunotherapy combined with chemotherapy is now the standard of care for resectable non-small...
Virtual multiplex immunofluorescence characterization of spatial immune architectures and tertiary lymphoid structures in high-grade serous ovarian cancer.
5585 Background: GigaTIME ( Cell , 2026) is a deep learning–based virtual multiple...
Global affordability of the ASCO Annual Meeting: A longitudinal analysis over 5 years.
e23160 Background: International oncology conferences shape scientific careers, guideline adoption, and global research ne...
National perspectives on artificial intelligence use in cancer care: Confidence, adoption, and barriers.
e13648 Background: Artificial intelligence (AI) in cancer care offers opportunities to reduce administrative burden, impro...
Validation of a droplet digital PCR test for monitoring ESR1 ctDNA variants in blood.
e13066 Background: Estrogen receptor 1 (ESR1) mutations represent a critical mechanism of acquired resistance to aromatase...
Transportation access as a structural determinant of quality of life and symptom burden among cancer patients.
1536 Background: Growing evidence links the built environment to cancer outcomes, with NCCN recommendations emphasizing th...
Real-world characteristics, treatment patterns, and outcomes of renal cell carcinoma at a high-complexity center in southwestern Colombia.
e16548 Background: Real-world data on renal cell carcinoma (RCC) in Latin America are limited, despite the widespread adop...
Sociodemographic disparities and clinical outcomes in chimeric antigen receptor (CAR) T-cell therapy: A real-world study at a diverse academic cancer center.
e23435 Background: Chimeric Antigen Receptor T-cell (CAR-T) therapy is an effective treatment for relapsed/refractory hema...
Machine learning/artificial intelligence in liquid-biopsy–based cancer screening.
e22576 Background: Early diagnosis is vital for cancer prognosis, yet high-level screening evidence (Grade A/B) currently...
Molecular characterization and treatment patterns of lung cancer in solid organ transplant (SOT) recipients.
e20699 Background: SOT recipients are at increased risk of malignancy due to immunosuppression. Lung cancer is among the m...
Alpha-fetoprotein as a biomarker of response to first-line chemoimmunotherapy in metastatic hepatocellular carcinoma.
e16247 Background: Atezolizumab plus bevacizumab (Atezo/Bev) and durvalumab plus tremelimumab (Durva/Tremi) are preferred...
Enhanced surveillance modalities and biopsy outcomes.
e12749 Background: Breast cancer (BC) survivors are at higher risk for recurrence or new primary disease and often require...
Sequencing ivosidenib post–first-line immunotherapy in biliary tract cancer: A real-world matched analysis.
e16249 Background: The TOPAZ-1 trial established Gemcitabine-Cisplatin plus Durvalumab as the preferred first-line therapy...
Multi-omic ctDNA-based MRD for predicting clinical outcomes in advanced NSCLC receiving chemoimmunotherapy.
8576 Background: Immune checkpoint inhibitors (ICIs) have revolutionized treatment for advanced non–small cell lung cancer...
Fixed-duration glofitamab monotherapy in relapsed/refractory (R/R) mantle cell lymphoma (MCL) with/without prior Bruton's tyrosine kinase inhibitor (BTKi) exposure: Updated data after a 3.5-year follow-up.
7006 Background: Patients (pts) with advanced R/R MCL have poor outcomes, especially pts with high-risk features or those...